TAGX 0004
Alternative Names: TAGX-0004Latest Information Update: 19 Jul 2023
At a glance
- Originator TagCyx Biotechnologies
- Class DNA; Nucleic acids
- Mechanism of Action Von Willebrand factor modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Thrombotic thrombocytopenic purpura
- Discontinued Von Willebrand disease
Most Recent Events
- 19 Jul 2023 Discontinued - Preclinical for Von Willebrand disease in Japan (unspecified route)
- 19 Jul 2023 Preclinical trials in Thrombotic thrombocytopenic purpura in Japan, prior to July 2023 (unspecified route) (TagCys Biotechnologies pipeline, July 2023)
- 19 Jul 2023 Pharmacodynamics data from a preclinical studies inThrombotic thrombocytopenic purpurareleased by TagCys Biotechnologies (TagCys Biotechnologies pipeline, July 2023)